American Healthcare REIT (NYSE:AHR) Given New $47.00 Price Target at Scotiabank

Key Points

• Scotiabank has increased the price target for American Healthcare REIT (AHR) from $42.00 to $47.00, indicating a potential upside of 10.26% from the current trading price.
• Several other firms, including Royal Bank of Canada and Morgan Stanley, have also raised their price targets for AHR, with most analysts giving it a consensus rating of “Buy”.
• In its latest quarterly earnings, American Healthcare REIT reported an EPS of $0.42, exceeding analyst expectations, with revenue of $542.50 million, up 7.5% compared to the previous year.

American Healthcare REIT (NYSE:AHR - Get Free Report) had its price target increased by analysts at Scotiabank from $42.00 to $47.00 in a note issued to investors on Thursday,Benzinga reports. The firm currently has a "sector outperform" rating on the stock. Scotiabank's price objective points to a potential upside of 10.26% from the company's previous close.

A number of other equities research analysts have also commented on the stock. Royal Bank Of Canada upped their price target on shares of American Healthcare REIT from $39.00 to $45.00 and gave the company an "outperform" rating in a report on Wednesday, August 13th. Morgan Stanley upped their price target on shares of American Healthcare REIT from $37.00 to $45.00 and gave the company an "overweight" rating in a report on Tuesday, May 20th. JMP Securities upped their price target on shares of American Healthcare REIT from $40.00 to $45.00 and gave the company a "market outperform" rating in a report on Monday, August 11th. Truist Financial upped their price target on shares of American Healthcare REIT from $44.00 to $46.00 and gave the company a "buy" rating in a report on Tuesday. Finally, Robert W. Baird started coverage on shares of American Healthcare REIT in a report on Friday, July 18th. They set an "outperform" rating and a $41.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating and ten have issued a Buy rating to the company's stock. According to MarketBeat.com, American Healthcare REIT currently has a consensus rating of "Buy" and an average target price of $41.89.

American Healthcare REIT Price Performance

AHR stock traded down $0.11 during midday trading on Thursday, reaching $42.63. The company had a trading volume of 155,418 shares, compared to its average volume of 1,633,516. The company has a debt-to-equity ratio of 0.41, a current ratio of 0.48 and a quick ratio of 0.48. American Healthcare REIT has a 1 year low of $20.15 and a 1 year high of $43.14. The company has a market capitalization of $7.19 billion, a P/E ratio of -193.77, a P/E/G ratio of 2.18 and a beta of 1.08. The firm has a 50-day moving average price of $38.47 and a 200-day moving average price of $33.79.

American Healthcare REIT (NYSE:AHR - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported $0.42 EPS for the quarter, topping analysts' consensus estimates of $0.40 by $0.02. American Healthcare REIT had a negative net margin of 1.56% and a negative return on equity of 1.43%. The business had revenue of $542.50 million during the quarter, compared to analysts' expectations of $539.49 million. During the same quarter in the previous year, the company earned $0.33 EPS. The business's quarterly revenue was up 7.5% compared to the same quarter last year. American Healthcare REIT has set its FY 2025 guidance at 1.640-1.680 EPS. On average, research analysts anticipate that American Healthcare REIT will post 1.41 earnings per share for the current fiscal year.

Insider Buying and Selling at American Healthcare REIT

In other news, CIO Stefan K.L. Oh sold 3,860 shares of the company's stock in a transaction dated Monday, June 30th. The shares were sold at an average price of $36.10, for a total value of $139,346.00. Following the sale, the executive directly owned 95,671 shares of the company's stock, valued at $3,453,723.10. This represents a 3.88% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 0.92% of the stock is owned by corporate insiders.

Institutional Trading of American Healthcare REIT

Several institutional investors have recently bought and sold shares of AHR. Stratos Wealth Partners LTD. boosted its holdings in American Healthcare REIT by 57.9% in the first quarter. Stratos Wealth Partners LTD. now owns 16,070 shares of the company's stock worth $487,000 after purchasing an additional 5,891 shares during the last quarter. GAMMA Investing LLC raised its stake in American Healthcare REIT by 42.2% during the 1st quarter. GAMMA Investing LLC now owns 1,405 shares of the company's stock valued at $43,000 after buying an additional 417 shares during the last quarter. Kingswood Wealth Advisors LLC bought a new position in shares of American Healthcare REIT during the 1st quarter valued at $332,000. Sequoia Financial Advisors LLC purchased a new position in shares of American Healthcare REIT in the 1st quarter worth $476,000. Finally, Charles Schwab Investment Management Inc. boosted its stake in shares of American Healthcare REIT by 4.2% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 2,235,051 shares of the company's stock worth $67,722,000 after buying an additional 89,926 shares during the last quarter. 16.68% of the stock is owned by hedge funds and other institutional investors.

American Healthcare REIT Company Profile

Formed by the successful merger of Griffin-American Healthcare REIT III and Griffin-American Healthcare REIT IV, as well as the acquisition of the business and operations of American Healthcare Investors, American Healthcare REIT is one of the larger healthcare-focused real estate investment trusts globally with assets totaling approximately $4.2 billion in gross investment value.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.